REG - Craneware plc - H1 FY26 Trading Update and Notice of Results

CranewareAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST5109Pa&default-theme=true

RNS Number : 5109P  Craneware plc  20 January 2026

Craneware plc

("Craneware", the "Company" or the "Group")

 

H1 FY26 Trading Update and Notice of Results

 

20 January 2026 - Craneware (AIM: CRW.L), a leader in healthcare financial
performance solutions, is pleased to provide an update on trading for the six
months ended 31 December 2025 ("H1 FY26").

 

Trading Update

 

Craneware is pleased to announce a strong performance for the six months ended
31 December 2025, delivering year-on-year revenue growth of 6% to c.$106m (H1
FY25: $100m) and double-digit growth in Adjusted EBITDA(1) to approximately
$33.4m (H1 FY25: $30.3m). This reflects continued execution of the Group's
strategic priorities and sustained demand across its core markets. Annual
Recurring Revenue ("ARR(2")) has, so far, grown by approximately 4% to
c.$184.3m (H1 FY25: $177.3m), with continued sales and Net Revenue Retention
above 100%.

 

The Group continues to deliver high levels of operating cash conversion, which
has been used to invest in its product portfolio, reduce debt and interest
costs, with total bank debt reduced to $23.4m (H1 FY25: $31.6m), whilst
retaining healthy total cash reserves of $71.2m (H1 FY25: $72.2m) after
adjusting for cash in transit of $30.3m.

 

Against a backdrop of global economic uncertainty, Craneware has maintained
momentum through ongoing investment in innovation, operational efficiency, and
disciplined cost management. The Group's ability to navigate macroeconomic
challenges underscores the resilience of its business model and strength of
customer relationships.

 

The introduction of the Health Resources and Services Administration ("HRSA")
Rebate Model Pilot, which aimed to reshape reimbursement dynamics within the
US 340B program, was stayed by a US District court and in turn, HRSA has
announced a temporary halt to the pilot programme, giving welcome short-term
clarity for healthcare providers. While this halt has impacted the Group's
reported revenue and recurring revenue growth for the period, relating to
signed sales contracts in this area, the speed at which the Group was able to
launch a fully viable Rebate solution to protect its customers, demonstrates
the depth of data and technical strength of the Trisus platform, and the
team's commitment to customer success.

 

Outlook

 

Craneware continues to trade in line with current market expectations for the
year ending 30 June 2026. The Group is on track to deliver double-digit growth
in the near term, supported by a robust pipeline, favourable market
conditions, and strategic initiatives that position the Company for
sustainable expansion.

 

The strength of the Company's balance sheet, high levels of recurring revenue
and strong cash generation has provided Craneware with solid foundations as it
continues to execute on its growth strategy, capitalising on its strategic
position at the heart of the US healthcare market.

 

Notice of Results

 

Craneware will announce results for the six months ended 31 December 2025 on 2
March 2026.

 

Keith Neilson, CEO of Craneware plc, commented,

 

"We are pleased to have delivered another healthy first half performance,
which combined with the strength of our recurring revenue model provides
confidence in near-term, sustainable double-digit growth, as customers
increase their use of our Trisus platform and platform partner offerings.
Through our continued innovation, including collaborations with Microsoft and
Oracle, we are ideally positioned to support our customers in the evolving
landscape of US Healthcare.

 

"With continued sales successes, ARR growth and continued strong cash
generation, we are well positioned to leverage our strategic position as a
powerful source of independent data and insights at the heart of the US
healthcare market. We look to the future with confidence."

 

(1) Adjusted EBITDA refers to earnings before interest, tax, depreciation,
amortisation, share based payments and acquisition and integration related
costs

(2) Annual Recurring Revenue ("ARR") includes the annual value of licence and
transaction revenues as at 31 December 2025 that are subject to underlying
contracts.

 

For further information, please contact:

 

 Craneware plc                                     +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications                     +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Sarah Peters      craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)                +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                  +44 (0)20 7597 5970
 Patrick Robb, Virginia Bull, Arnav Kapoor
 ( )                                               ( )
 Berenberg (Joint Broker)                          +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Patrick Dologhan

 

About Craneware

 

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus® cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth. As a trusted Microsoft
partner, we provide future-ready solutions-including the Best in KLAS Trisus
Chargemaster - that simplify the complexities of healthcare finance and
operations. What sets us apart is our unique combination of deep healthcare
expertise and engineering excellence, positioning us as a strategic partner
rather than just a technology provider. The Craneware Group empowers
healthcare organizations to achieve sustainable financial success while
delivering better outcomes for the communities they serve - today and in the
future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTGZGMMMLMGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved